使用决策辅助工具的患者完成肺癌查:系统性审查和元分析
Alexander Antigua-Made1, Sabrina Nguyen2, Ali Rashidi3
1Anne Burnett School of Medicine, Texas Christian University, Fort Worth, TX, USA.
Cancer causes & control : CCC
|March 18, 2025
概括
患者决策辅助工具 (PDA) 显著增加了肺癌查完成率和完成查的意图. 实施PDA可以改善符合条件的个人对LCS的采用.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
背景情况:
- 肺癌查 (LCS) 的利用率仍然很低,只有16%的符合条件的患者在2022年接受查.
- 患者决策辅助器 (PDA) 是旨在帮助患者做出明智的医疗保健选择的工具.
研究的目的:
- 系统地审查和元分析PDA对LCS完成率的影响.
- 评估PDAs对符合条件的患者中完成LCS的意图的影响.
主要方法:
- 对2011年1月至2023年2月期间发表的研究进行了多个数据库 (PubMed,Cochrane,Scopus,CINAHL,Web of Science) 的系统搜索.
- 包括随机对照试验和前性队列研究,评估LCS的PDA干预措施.
- 数据被提取并独立评估质量,随后进行随机效应模型元分析.
主要成果:
- 包含2277名参与者的13项研究被纳入了元分析.
- 在使用PDA的患者中,LCS完成率是40% (95% CI,15-65%).
- 完成LCS的整体意图为57% (95% CI,34%至80%),在两个结果中观察到显著的异质性.
结论:
- 使用PDA与高LCS完成率和完成LCS的意图有关.
- 建议在临床实践中实施PDA,以加强共享决策并改善LCS的吸收.
- PDA可以成为克服LCS障碍和增加符合条件人群查率的宝贵工具.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
196
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.3K
相关概念视频
01:25Statistical Methods for Analyzing Epidemiological Data
268
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
268
01:21Cancer Survival Analysis
315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315
01:12Hazard Ratio
72
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
72